Hepatitis Monthly

Published by: Kowsar
Uncorrected Proof scheduled for 18 (7)

IgG4 Status in Explanted Livers Does Not Affect the Outcome of Primary Sclerosing Cholangitis (PSC) After Liver Transplant

Bandar Al-Judaibi 1 , 2 , * , Roberto Hernandez-Alejandro 2 , Chaturika Herath 3 , Subrata Chakrabarti 3 , Katherine Dokus 2 , Paul Marotta 1 and Mansour Alghanem 1
Authors Information
1 Division of Gastroenterology, Department of Medicine, Western University, Ontario, Canada
2 Division of Transplant, University of Rochester, Rochester, New York, United States of America
3 Department of Pathology, Western University Ontario, Ontario, Canada
Article information
  • Hepatitis Monthly: , In Press (In Press); e66037
  • Published Online: June 12, 2018
  • Article Type: Research Article
  • Received: January 8, 2018
  • Revised: April 29, 2018
  • Accepted: May 1, 2018
  • DOI: 10.5812/hepatmon.66037

To Cite: Al-Judaibi B, Hernandez-Alejandro R, Herath C, Chakrabarti S, Dokus K, et al. IgG4 Status in Explanted Livers Does Not Affect the Outcome of Primary Sclerosing Cholangitis (PSC) After Liver Transplant, Hepat Mon. Online ahead of Print ;In Press(In Press):e66037. doi: 10.5812/hepatmon.66037.

Abstract
Copyright © 2018, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Footnotes
References
  • 1. Lindor KD, Kowdley KV, Harrison ME, American College of G. ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol. 2015;110(5):646-59. quiz 660. doi: 10.1038/ajg.2015.112. [PubMed: 25869391].
  • 2. Pollheimer MJ, Halilbasic E, Fickert P, Trauner M. Pathogenesis of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2011;25(6):727-39. doi: 10.1016/j.bpg.2011.10.009. [PubMed: 22117638]. [PubMed Central: PMC3236286].
  • 3. Beuers U, Hubers LM, Doorenspleet M, Maillette de Buy Wenniger L, Klarenbeek PL, Boonstra K, et al. IgG4-Associated Cholangitis--A Mimic of PSC. Dig Dis. 2015;33 Suppl 2:176-80. doi: 10.1159/000440830. [PubMed: 26641633].
  • 4. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366(6):539-51. doi: 10.1056/NEJMra1104650. [PubMed: 22316447].
  • 5. Tabibian JH, Lindor KD. Primary sclerosing cholangitis: a review and update on therapeutic developments. Expert Rev Gastroenterol Hepatol. 2013;7(2):103-14. doi: 10.1586/egh.12.80. [PubMed: 23363260].
  • 6. Nishino T, Oyama H, Hashimoto E, Toki F, Oi I, Kobayashi M, et al. Clinicopathological differentiation between sclerosing cholangitis with autoimmune pancreatitis and primary sclerosing cholangitis. J Gastroenterol. 2007;42(7):550-9. doi: 10.1007/s00535-007-2038-8. [PubMed: 17653651].
  • 7. Esposito I, Born D, Bergmann F, Longerich T, Welsch T, Giese NA, et al. Autoimmune pancreatocholangitis, non-autoimmune pancreatitis and primary sclerosing cholangitis: a comparative morphological and immunological analysis. PLoS One. 2008;3(7). e2539. doi: 10.1371/journal.pone.0002539. [PubMed: 18596913]. [PubMed Central: PMC2440515].
  • 8. Kawa S, Hamano H, Umemura T, Kiyosawa K, Uehara T. Sclerosing cholangitis associated with autoimmune pancreatitis. Hepatol Res. 2007;37 Suppl 3:S487-95. doi: 10.1111/j.1872-034X.2007.00235.x. [PubMed: 17931208].
  • 9. Mendes FD, Jorgensen R, Keach J, Katzmann JA, Smyrk T, Donlinger J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006;101(9):2070-5. doi: 10.1111/j.1572-0241.2006.00772.x. [PubMed: 16879434].
  • 10. Williamson KD, Chapman RW. Primary sclerosing cholangitis: a clinical update. Br Med Bull. 2015;114(1):53-64. doi: 10.1093/bmb/ldv019. [PubMed: 25981516].
  • 11. Mendes F, Lindor KD. Primary sclerosing cholangitis: overview and update. Nat Rev Gastroenterol Hepatol. 2010;7(11):611-9. doi: 10.1038/nrgastro.2010.155. [PubMed: 20938459].
  • 12. Chen JH, Deshpande V. IgG4-related Disease and the Liver. Gastroenterol Clin North Am. 2017;46(2):195-216. doi: 10.1016/j.gtc.2017.01.001. [PubMed: 28506361].
  • 13. Zhang L, Lewis JT, Abraham SC, Smyrk TC, Leung S, Chari ST, et al. IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis. Am J Surg Pathol. 2010;34(1):88-94. doi: 10.1097/PAS.0b013e3181c6c09a. [PubMed: 20035148].
  • 14. Deshpande V. The pathology of IgG4-related disease: critical issues and challenges. Semin Diagn Pathol. 2012;29(4):191-6. doi: 10.1053/j.semdp.2012.08.001. [PubMed: 23068297].
  • 15. Ohara H, Okazaki K, Tsubouchi H, Inui K, Kawa S, Kamisawa T, et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci. 2012;19(5):536-42. doi: 10.1007/s00534-012-0521-y. [PubMed: 22717980].
  • 16. Chung H, Watanabe T, Kudo M, Maenishi O, Wakatsuki Y, Chiba T. Identification and characterization of IgG4-associated autoimmune hepatitis. Liver Int. 2010;30(2):222-31. doi: 10.1111/j.1478-3231.2009.02092.x. [PubMed: 19650840].
  • 17. Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181-92. doi: 10.1038/modpathol.2012.72. [PubMed: 22596100].
  • 18. Chandok N, Hirschfield GM. Management of primary sclerosing cholangitis: conventions and controversies. Can J Gastroenterol. 2012;26(5):261-8. [PubMed: 22590699]. [PubMed Central: PMC3352841].
  • 19. Al-Judaibi B, Hernandez Alejandro R, Uhanova J, Marotta P, Mosli M, Chandok N. Duct-to-Duct Biliary Anastomosis Yields Similar Outcomes to Roux-en-Y Hepaticojejunostomy in Liver Transplantation for Primary Sclerosing Cholangitis. Hepat Mon. 2015;15(5). e18811. doi: 10.5812/hepatmon.15(5)2015.18811. [PubMed: 26045700]. [PubMed Central: PMC4451269].
  • 20. Graziadei IW, Wiesner RH, Batts KP, Marotta PJ, LaRusso NF, Porayko MK, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology. 1999;29(4):1050-6. doi: 10.1002/hep.510290427. [PubMed: 10094945].
  • 21. Gelley F, Zadori G, Gorog D, Kobori L, Fehervari I, Gaman G, et al. Recurrence of primary sclerosing cholangitis after liver transplantation - The Hungarian experience. Interv Med Appl Sci. 2014;6(1):16-8. doi: 10.1556/IMAS.6.2014.1.2. [PubMed: 24672670]. [PubMed Central: PMC3955810].
  • 22. Alabraba E, Nightingale P, Gunson B, Hubscher S, Olliff S, Mirza D, et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl. 2009;15(3):330-40. doi: 10.1002/lt.21679. [PubMed: 19243003].
  • 23. Ravikumar R, Tsochatzis E, Jose S, Allison M, Athale A, Creamer F, et al. Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. J Hepatol. 2015;63(5):1139-46. doi: 10.1016/j.jhep.2015.07.005. [PubMed: 26186988].
  • 24. Fischer S, Trivedi PJ, Ward S, Greig PD, Therapondos G, Hirschfield GM. Frequency and significance of IgG4 immunohistochemical staining in liver explants from patients with primary sclerosing cholangitis. Int J Exp Pathol. 2014;95(3):209-15. doi: 10.1111/iep.12076. [PubMed: 24750423]. [PubMed Central: PMC4351857].
  • 25. Bjornsson E, Chari S, Silveira M, Gossard A, Takahashi N, Smyrk T, et al. Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther. 2011;18(3):198-205. doi: 10.1097/MJT.0b013e3181c9dac6. [PubMed: 20228674].
  • 26. Hamano H, Umemura T, Uehara T, Kawa S, Kiyosawa K. IgG4-related sclerosing cholangitis should be included as an exclusion criterion for the diagnosis of primary sclerosing cholangitis. Am J Gastroenterol. 2007;102(3):691-2. doi: 10.1111/j.1572-0241.2007.01040_8.x. [PubMed: 17335458].
  • 27. Doorenspleet ME, Hubers LM, Culver EL, Maillette de Buy Wenniger LJ, Klarenbeek PL, Chapman RW, et al. Immunoglobulin G4(+) B-cell receptor clones distinguish immunoglobulin G 4-related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies. Hepatology. 2016;64(2):501-7. doi: 10.1002/hep.28568. [PubMed: 27015613]. [PubMed Central: PMC5017301].
  • 28. Ghazale A, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levy MJ, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134(3):706-15. doi: 10.1053/j.gastro.2007.12.009. [PubMed: 18222442].
  • 29. Oh HC, Kim MH, Lee KT, Lee JK, Moon SH, Song TJ, et al. Clinical clues to suspicion of IgG4-associated sclerosing cholangitis disguised as primary sclerosing cholangitis or hilar cholangiocarcinoma. J Gastroenterol Hepatol. 2010;25(12):1831-7. doi: 10.1111/j.1440-1746.2010.06411.x. [PubMed: 21091993].
  • 30. Boonstra K, Culver EL, de Buy Wenniger LM, van Heerde MJ, van Erpecum KJ, Poen AC, et al. Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatology. 2014;59(5):1954-63. doi: 10.1002/hep.26977. [PubMed: 24375491]. [PubMed Central: PMC4489327].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments